These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37190755)

  • 41. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small molecule inhibitors of the p53-MDM2.
    Hu CQ; Hu YZ
    Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018).
    Skalniak L; Surmiak E; Holak TA
    Expert Opin Ther Pat; 2019 Mar; 29(3):151-170. PubMed ID: 30822185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent advances in validating MDM2 as a cancer target.
    Rayburn ER; Ezell SJ; Zhang R
    Anticancer Agents Med Chem; 2009 Oct; 9(8):882-903. PubMed ID: 19538162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy.
    Wang W; Zafar A; Rajaei M; Zhang R
    Cells; 2020 May; 9(5):. PubMed ID: 32397368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
    Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
    J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
    Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
    He S; Dong G; Wu S; Fang K; Miao Z; Wang W; Sheng C
    J Med Chem; 2018 Aug; 61(16):7245-7260. PubMed ID: 30045621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
    Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA
    Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
    Lemos A; Gomes AS; Loureiro JB; Brandão P; Palmeira A; Pinto MMM; Saraiva L; Sousa ME
    Molecules; 2019 May; 24(10):. PubMed ID: 31121972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
    Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
    Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of SCY45, a Natural Small-Molecule MDM2-p53 Interaction Inhibitor.
    Gong H; An J; Dong Q; Li J; Yang W; Sun W; Su Z; Zhang S
    Chem Biodivers; 2019 Jun; 16(6):e1900081. PubMed ID: 30989812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
    Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
    Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
    Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.